What question did this study set out to answer?

To evaluate the feasibility and safety of transitioning patients with PNH from pegcetacoplan to iptacopan.

February 11, 2026Open Access

Switching patients with PNH from pegcetacoplan to iptacopan: a case series

Puntos clave

To evaluate the feasibility and safety of transitioning patients with PNH from pegcetacoplan to iptacopan.
Observed three patients with PNH
Transitioned patients from pegcetacoplan to iptacopan
Monitored laboratory evidence of BTH, EVH, and intravascular hemolysis
No patients exhibited laboratory evidence of BTH after the switch
No evidence of EVH was observed
There was no intravascular hemolysis reported post-transition

Resumen

In this case series, three patients with PNH were successfully transitioned from pegcetacoplan to iptacopan monotherapy. No patients exhibited laboratory evidence of BTH, EVH, or intravascular hemolysis after switching to iptacopan.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Orland et al. (Mon,) studied this question.

synapsesocial.com/papers/698c1c73267fb587c655ee75 https://doi.org/https://doi.org/10.1080/16078454.2026.2618403

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo